PMID- 17552959
OWN - NLM
STAT- MEDLINE
DCOM- 20070813
LR  - 20151119
IS  - 1464-4096 (Print)
IS  - 1464-4096 (Linking)
VI  - 100
IP  - 1
DP  - 2007 Jul
TI  - Analysis of the efficacy and safety of sildenafil citrate in the geriatric 
      population.
PG  - 117-21
AB  - OBJECTIVE: To define the efficacy and tolerability of sildenafil in elderly men, 
      as epidemiological data show an increasing life-expectancy of the population, and 
      age is not only correlated with increasing morbidity but also an increase in the 
      prevalence of erectile dysfunction (ED), for which sildenafil, available for >8 
      years, is effective and safe across a wide variety of medical comorbidities, 
      severity and causes of ED. PATIENTS AND METHODS: A database was generated from 
      all sildenafil users in one sexual medicine practice, and data were extracted for 
      men aged >60 years. The database included data on patient demographics, 
      comorbidities, International Index of Erectile Function (IIEF) scores and adverse 
      events (AEs). The patients were subdivided into those aged 60-69 (group 1), 70-79 
      (group 2), and > or = 80 years (group 3). Analysis of variance was used to assess 
      differences among the three groups for several variables of demographics and 
      erectile response. RESULTS: In all, 167 patients were analysed; there were no 
      significant differences in the duration of ED (5 +/- 3 years) or presence of 
      comorbidities among the three groups. With a mean of two risk factors, the 
      overall incidence of comorbidities was hypertension in 37%, dyslipidaemia in 28%, 
      diabetes in 26%, coronary artery disease in 18% and lower urinary tract symptoms 
      in 46%. The efficacy data showed that overall, 54% of men responded to 
      sildenafil, with a mean increase in IIEF EF domain score of 5.7. Within the three 
      groups there was a significant age-related decrease in response rate and IIEF EF 
      domain score with age. However, there was no difference in AE incidence among the 
      three groups, with an overall profile of 18% headache, 8% flushing, 8% dyspepsia, 
      5% nasal congestion and 2% visual changes. No overt cardiovascular events were 
      reported. CONCLUSIONS: From these data, sildenafil is an effective agent in 
      elderly men, but had a lower efficacy rate with increasing age, especially in men 
      aged >80 years. The incidence of side-effects was similar to that in the general 
      population taking sildenafil, with no difference in AEs among the different age 
      groups.
FAU - Muller, Alexander
AU  - Muller A
AD  - Department of Urology, Weill Medical College of Cornell University, New York 
      Presbyterian Hospital, 525 E. 68th Street, New York, NY 10021, USA.
FAU - Smith, Lizette
AU  - Smith L
FAU - Parker, Marilyn
AU  - Parker M
FAU - Mulhall, John P
AU  - Mulhall JP
LA  - eng
PT  - Journal Article
PL  - England
TA  - BJU Int
JT  - BJU international
JID - 100886721
RN  - 0 (Phosphodiesterase Inhibitors)
RN  - 0 (Piperazines)
RN  - 0 (Purines)
RN  - 0 (Sulfones)
RN  - BW9B0ZE037 (Sildenafil Citrate)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Aging/*physiology
MH  - Analysis of Variance
MH  - Databases as Topic
MH  - Erectile Dysfunction/*drug therapy
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Penile Erection/drug effects/physiology
MH  - Phosphodiesterase Inhibitors/adverse effects/*therapeutic use
MH  - Piperazines/adverse effects/*therapeutic use
MH  - Purines/adverse effects/therapeutic use
MH  - Risk Factors
MH  - Sildenafil Citrate
MH  - Sulfones/adverse effects/*therapeutic use
MH  - Surveys and Questionnaires
MH  - Treatment Outcome
EDAT- 2007/06/08 09:00
MHDA- 2007/08/19 09:00
CRDT- 2007/06/08 09:00
PHST- 2007/06/08 09:00 [pubmed]
PHST- 2007/08/19 09:00 [medline]
PHST- 2007/06/08 09:00 [entrez]
AID - BJU6915 [pii]
AID - 10.1111/j.1464-410X.2007.06915.x [doi]
PST - ppublish
SO  - BJU Int. 2007 Jul;100(1):117-21. doi: 10.1111/j.1464-410X.2007.06915.x.